ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced that its management will participate in a fireside chat at the 3rd Annual Evercore ISI Virtual HealthCONx Conference. The event is scheduled for December 2, 2020, at 3:55 PM EST and will be webcast live. Following the presentation, an archived version will be accessible for 30 days on ProQR's website. ProQR focuses on developing RNA therapies for inherited retinal diseases utilizing its proprietary RNA repair platform.
- None.
- None.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming 3rd Annual Evercore ISI Virtual HealthCONx Conference. The presentation will be webcast live on December 2, 2020 at 3:55pm EST.
The live and archived webcast of the presentation will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under ‘Events’. The archived webcast will be available for approximately 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 535 7743
hans@lifesciadvisors.com
Media Contact:
Alison Chen
LifeSci Communications
T: +1 646 876 4932
achen@lifescicomms.com
FAQ
What is ProQR Therapeutics presenting at the Evercore ISI Virtual HealthCONx Conference?
When will ProQR's presentation take place?
How can I access the ProQR Therapeutics presentation?
What therapies does ProQR Therapeutics focus on?
What is the stock symbol for ProQR Therapeutics?
